University of Nottingham
What are the possible modes of operating a commercial-scale distributed business for bioprinting implants containing living cells? To what extent could the existing non-routine arrangements be used for commercialisation of personalised Advanced Therapy Medicinal Products (ATMPs)? What are the needs in relation to the development of a more appropriate framework for regulation of customised products? Watch the video to learn more.